RSS-Feed abonnieren
DOI: 10.1055/s-0037-1616899
Erste Ergebnisse der THROMKID-Studie
Qualitätsprojekt zur Erfassung von Kindern und Jugendlichen mit angeborenen Thrombozytenfunktionsstörungen in Deutschland, Österreich und der SchweizFirst results of the THROMKID studyA quality project for the registration of children und adolescents with hereditary platelet function defects in Germany, Austria, and SwitzerlandPublikationsverlauf
Publikationsdatum:
27. Dezember 2017 (online)
Zusammenfassung
Im Rahmen der THROMKID-Studie als Qualitätsprojekt der Ständigen Kommission Pädiatrie der Gesellschaft für Thrombose- und Hämostaseforschung (GTH) wurden Daten pädiatrischer Patienten mit hereditären Thrombozytopathien zwischen Mai 2005 und August 2006 erfasst. Die Ergebnisse der Thrombozytenfunktionsdiagnostik wurden bei jedem Patienten bewertet und die Diagnosen als sehr wahrscheinlich, wahrscheinlich oder unwahrscheinlich eingestuft. Von insgesamt 215 Patienten aus 31 Zentren war bei 95 (44%) die Diagnose sehr wahrscheinlich und bei 28 (13%) wahrscheinlich. Folgende Erkrankungen wurden erfasst: Thrombasthenie Glanzmann (n = 39, 32%), Aspirin- like Defekt (n = 26, 21%), thrombozytäre Rezeptordefekte (n = 21, 17%), Storage-pool-Defekte (n = 18, 15%), Bernard-Soulier Syndrom (n=10, 8%), Hermansky-Pudlak-Syndrom (n = 6, 5%) und MYH9-assoziierte Makrothrombozytopenie (n = 3, 2%). Bei 92 (43%) Patienten war die Diagnose unwahrscheinlich.
Die geringe Prävalenz dieser Erkrankungen und der hohe Prozentsatz nicht klassifizierbarer Krankheitsentitäten zeigt die Notwendigkeit, ein Kompetenznetzwerk zur Betreuung dieser Kinder in deutschsprachigen Ländern zu etablieren.
Summary
THROMKID is a quality project of the Paediatric Group of German Thrombosis and Haemostasis Research Society (GTH). Data from paediatric patients with hereditary thrombocytopathies (HT) treated in Germany, Austria, and Switzerland were obtained between May 2005 and August 2006. By evaluation of results of platelet function tests criteria were determined to assess the diagnosis in each patient into most likely, likely or unlikely. A total of 215 patients treated in 31 centers were identified. In 95 patients (44%) the diagnosis of HT was most likely, in 28 (13%) likely and in 92 (43%) unlikely. Taken the first two groups together (n = 123) the diagnoses were as follows: Glanzmann thrombasthenia (n = 39, 32%), Aspirin-like defect (n = 26, 21%), thrombocyte receptor defects (n = 21, 17%), storage pool disorders (n = 18, 15%), Bernard- Soulier syndrome (n = 10, 8%), Hermansky-Pudlak syndrome (n = 6, 5%) and MYH9-related hereditary makrothrombocytopenia (n = 3, 2%).
The low prevalence of these diseases and the high percentage of patients with unclassified HT stresses the necessity for the establishment of a competence network for comprehensive care of these patients in the three German-speaking countries.
-
Literatur
- 1 Balduini CL, Iolascon A, Savoia A. Inherited thrombocytopenias: from genes to therapy. Haematologica 2002; 87: 860-80.
- 2 Ballmaier M, Balduini C, Welte K. et al. Erblich bedingte Thrombozytopenien. Monatsschr Kinderheilkd 2006; 154: 510-21.
- 3 Dyszkiewicz-Korpanty AM, Frenkel EP, Sarode R. Approach to the assessment of platelet function: comparison between optical-based plateletrich plasma and impedance-based whole blood platelet aggregation methods. Clin Appl Thromb Hemost 2005; 11: 25-35.
- 4 Hayward CPM, Rao AK, Cattaneo M. Congenital platelet disorders: overview of their mechanisms, diagnostic evaluation and treatment. Haemophilia 2006; 12: 128-36.
- 5 Knöfler R, Weissbach G, Kuhlisch E. Platelet function tests in childhood. Measuring aggregation and release reaction in whole blood. Semin Thromb Hemost 1998; 6: 513-21.
- 6 Knöfler R, Siegert G, Kuhlisch E. et al. Diagnostics of platelet function disorders by lumi-aggregometry – Results and comparison of methods. In: Scharrer I, Schramm W. (eds). 34th Hemophilia Symposium Hamburg 2003. Heidelberg: Springer; 2005: 107-15.
- 7 Moffat KA, Ledford-Kraemer MR, Nichols WL. et al. Variability in clinical laboratory practice in testing for disorders of platelet function. Thromb Haemost 2005; 93: 549-53.
- 8 Nurden AT. Qualitative disorders of platelet and megakaryocytes. J Thromb Haemost 2005; 3: 1773-82.
- 9 Quiroga T, Goycoolea M, Munoz B. et al. Template bleeding time and PFA-100 have low sensitivity to screen patients with hereditary mucocutaneous hemorrhages: comparative study in 148 patients. J Thromb Haemost 2004; 2: 892-8.
- 10 Sutor AH. The bleeding time in pediatrics. Semin Thromb Hemost 1998; 6: 531-43.
- 11 Rand ML, Carcao MD, Blanchette VS. Use of the PFA-100 in the assessement of primary plateletrelated hemostasis in a pediatric setting. Semin Thromb Hemost 1998; 24: 523-9.
- 12 Rand ML, Leung R, Packham MA. Platelet function assays. Transfus Apheresis Sci 2003; 28: 307-17.